Skip to content

Clinical

Phase 1 study results published in the Lancet report stable vision following a single dose gene therapy encoding anti-VEGF protein. 

Researchers at the University of Nevada, Reno School of Medicine and the Department of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital, has published safety… Read More »Phase 1 study results published in the Lancet report stable vision following a single dose gene therapy encoding anti-VEGF protein. 

Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization. 

Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have reported a publication… Read More »Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization.